Detalhe da pesquisa
1.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
Blood
; 143(20): 2059-2072, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437498
2.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441846
3.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 204(3): 898-909, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946611
4.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
5.
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Br J Haematol
; 203(4): 581-592, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608562
6.
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Haematologica
; 108(9): 2331-2342, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951163
7.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Am J Hematol
; 98(11): 1780-1790, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665752
8.
Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency.
Mycoses
; 66(12): 1029-1034, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550272
9.
Can we transfuse wisely in patients undergoing chemotherapy for acute leukemia or autologous stem cell transplantation?
Transfusion
; 59(7): 2308-2315, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31059586
10.
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.
Am J Hematol
; 98(4): E91-E94, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36661399
11.
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
Am J Hematol
; 96(2): E50-E53, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33156969
12.
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field.
Leuk Lymphoma
; : 1-13, 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38770970
13.
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN.
Leuk Res
; 142: 107518, 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38744144
14.
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
Cancer Med
; 13(5): e7093, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497538
15.
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Blood Adv
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513082
16.
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Clin Cancer Res
; 30(7): 1319-1326, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38300723
17.
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Lancet Haematol
; 11(3): e186-e195, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38316133
18.
Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges.
J Fungi (Basel)
; 9(4)2023 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37108918
19.
Germline Predisposition to Myelodysplastic Syndromes.
Cancer J
; 29(3): 143-151, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195770
20.
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
Blood Adv
; 7(11): 2378-2387, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35973199